<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02328131</url>
  </required_header>
  <id_info>
    <org_study_id>Hp-EuReg</org_study_id>
    <nct_id>NCT02328131</nct_id>
  </id_info>
  <brief_title>European Registry on the Management of Helicobacter Pylori Infection</brief_title>
  <official_title>European Registry on the Management of Helicobacter Pylori Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Javier P. Gisbert</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación de Investigación Biomédica - Hospital Universitario de La Princesa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The great diversity of regimens and treatment lines, the different efficacy of these, mostly
      due to the increase in bacterial antibiotic resistance and regional differences, requires a
      continuous critical analysis of clinical practice, evaluating systematically the efficacy and
      safety of the different regimens and the cost-effectiveness of the different
      diagnostic-therapeutic strategies. This will help in the design of an efficient and optimized
      treatment that will reduce number of re-treatments, diagnostic tests and the appearance of
      associated pathologies such as peptic ulcers, gastrointestinal bleeding and, probably,
      gastric cancers. Therefore, the evaluation of real clinical practice using
      non-interventionist registries will help to improve the design and organization of European
      Consensus on the management of H. pylori infection, which is the best way to establish
      healthcare efficiency.

      Primary aim

      To obtain a database registering systematically over a year a large and representative sample
      of routine clinical practice of European gastroenterologists in order to produce descriptive
      studies of the management of H. pylori infection.

      Secondary aims

        1. To evaluate H. pylori infection consensus and clinical guidelines implementation in
           different countries.

        2. To perform studies focused on epidemiology, efficacy and safety of the commonly used
           treatments to eradicate H. pylori.

        3. To evaluate accessibility to healthcare technologies and drugs used in the management of
           H. pylori infection.

        4. To allow the development of partial and specific analysis by the participating
           researchers after approval by the Registry's Scientific Committee

      Methodology Non-interventionist prospective multicentre international registry promoted by
      the European Helicobacter Study Group. A renowned gastroenterologist from each country was
      selected as Local Coordinator (30 countries). They will in turn select up to ten
      gastroenterologists per country that will register the routine clinical practice
      consultations they receive over 10 years in an electronic Case Report Form (e-CRF). Variables
      retrieved will include clinical, diagnostic, treatment, eradication confirmation and outcome
      data. The database will allow researchers to perform specific subanalysis after approval by
      the Scientific Committee of the study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Abstract

      Introduction: H. pylori selectively infects the human stomach mucosa, being the most
      prevalent chronic infection in the world. Its prevalence correlates with socioeconomic
      factors and it is higher in older individuals. H. pylori presence causes chronic gastritis in
      100% of infected patients and is the major cause of relevant diseases such as atrophic
      gastritis, peptic ulcer disease and gastric cancer; it is for this reason that from a public
      health standpoint it is considered a high impact pathogen, responsible of a significant
      morbidity and mortality. Nowadays there are Consensus and Clinical Guidelines regarding the
      infection management at a European level and in most of the states, but no data have shown
      the level of implementation of these recommendations. The high costs that this infection
      carries both socially and to the health system require the continuous and systematic
      assessment of the diagnostic and treatment strategies, as well as the accessibility to
      diagnostic methods and most efficient drugs.

      Aim: To register the treatment, diagnosis and management strategies of H. pylori infected
      adult patients in the Digestive Services outpatient clinics throughout Europe.

      Methods: Non-interventionist prospective multicentre international registry promoted by the
      European Helicobacter Study Group. A renowned gastroenterologist from each country was
      selected as Local Coordinator (30 countries). They will in turn select up to ten
      gastroenterologists per country that will register the routine clinical practice
      consultations they receive over 10 years in an electronic Case Report Form (e-CRF). Variables
      retrieved will include clinical, diagnostic, treatment, eradication confirmation and outcome
      data. The database will allow researchers to perform specific subanalysis after approval by
      the Scientific Committee of the study.

      INTRODUCTION

      H. pylori presence causes chronic gastritis in 100% of infected patients and is the major
      cause of relevant diseases such as atrophic gastritis, peptic ulcer disease and gastric
      cancer. H. pylori eradication prevents peptic ulcer recurrence and its complications, and
      decreases the incidence of gastric cancer. H. pylori eradication in patients with peptic
      ulcer or even functional or non-investigated dyspepsia is a cost-effective strategy.

      The most common clinical manifestation of H. pylori infection is dyspepsia, a major health
      problem, whose prevalence reaches more than 10% among adult populations with its attendant
      burden of morbidity and health system costs in diagnosis and treatment. Approximately 20% to
      30% of people in the community each year report chronic or recurrent dyspeptic symptoms, and
      consultations for dyspepsia account for up to 40% of referrals among gastroenterology
      outpatients, the &quot;test-and-treat&quot; strategy being the most cost-effective. Moreover, H. pylori
      is the major cause of peptic ulcer disease, causing over 90% of duodenal and 70% of gastric
      ulcers. Considerable evidence supports that the nature of the chronic inflammatory process
      driven by H. pylori is of critical importance in gastric carcinogenesis (adenocarcinoma and
      mucosa-associated lymphoid tissue -MALT- lymphoma). It is for that reason that the WHO's
      International Agency for Research on Cancer classified H. pylori as a group 1 (definite)
      carcinogen.

      Scientific evidence demonstrates that diagnosis and eradication of H. pylori is the most
      cost-effective strategy in the management of dyspepsia, peptic ulcer and gastric cancer
      prevention. The treatment regimens are very diverse and have changed overtime. Monotherapies
      and treatments with two drugs did not achieve acceptable eradication rates. The commonly
      recommended regimen in most Consensus Conferences is the standard triple regimen, combining
      two antibiotics (clarithromycin with amoxicillin or metronidazole) and a proton pump
      inhibitor (PPI) for 7 to 14 days. Another recommended alternative is bismuth-containing
      quadruple therapy (PPI, tetracycline, metronidazole and bismuth salts). In the last years,
      results with new and efficient rescue regimens including levofloxacin have been published.
      Lately, new treatments have been proposed, including non-bismuth quadruple regimens, with two
      main variants: the &quot;sequential&quot; treatment (an induction phase with PPI and amoxicillin and a
      second phase with PPI, clarithromycin and metronidazole) and the &quot;concomitant&quot; treatment
      (same four drugs taken altogether).

      The great diversity of regimens and treatment lines, the different efficacy of these, mostly
      due to the increase in bacterial antibiotic resistance and regional differences, requires a
      continuous critical analysis of clinical practice, evaluating systematically the efficacy and
      safety of the different regimens and the cost-effectiveness of the different
      diagnostic-therapeutic strategies. This will help in the design of an efficient and optimized
      treatment that will reduce number of re-treatments, diagnostic tests and the appearance of
      associated pathologies such as peptic ulcers, gastrointestinal bleeding and, probably,
      gastric cancers. Therefore, the evaluation of real clinical practice using
      non-interventionist registries will help to improve the design and organization of European
      Consensus on the management of H. pylori infection, which is the best way to establish
      healthcare efficiency.

      AIMS

      Primary aim To obtain a database registering systematically over a year a large and
      representative sample of routine clinical practice of European gastroenterologists in order
      to produce descriptive studies of the management of H. pylori infection.

      Secondary aims

        1. To evaluate H. pylori infection consensus and clinical guidelines implementation in
           different countries.

        2. To perform studies focused on epidemiology, efficacy and safety of the commonly used
           treatments to eradicate H. pylori.

        3. To evaluate accessibility to healthcare technologies and drugs used in the management of
           H. pylori infection.

        4. To allow the development of partial and specific analysis by the participating
           researchers after approval by the Registry's Scientific Committee.

      METHODS

      International multicenter prospective non-interventionist registry promoted by the European
      Helicobacter Study Group.

      Scientific Committee

        -  Javier P. Gisbert (President)

        -  Francis Megraud

        -  Colm O'Morain

        -  Adrian G. McNicholl

      Local Coordinators

      A list of European Countries has been selected. Included countries were those having at least
      ten clinical research publications in PubMed regarding H. pylori infection.

      In each country a Local Coordinator was selected based on its clinical and research activity
      (Table I).

      The Local Coordinators will constitute the monitoring and drafting committee of the registry.

      The Local Coordinators will be in charge of selecting up to 10 recruiting investigators in
      each country and will be in charge of the follow up and quality of the recruiting; they will
      be the link between promoters and recruiting investigators.

      Recruiter Investigators

      The Recruiting Investigators must be gastroenterologists attending an adult population with a
      gastroenterology outpatient clinic that assists H. pylori infected patients. Before
      acceptance the outpatient clinic must attend, in a clinical routine basis, patients in which
      H. pylori diagnosis or treatment is indicated. Eradication confirmation tests have to be
      performed routinely. They will register the study variables of their own routine clinical
      practice in an e-CRF.

      Study Variables

      Anonymised Patient Identifiers

        -  Country/Centre/Investigator

        -  Autonumeric Patient identifier number

        -  Gender

        -  Date of Birth

        -  Ethnic Background History and Comorbidity

        -  Drug allergies

        -  Relevant comorbidities

        -  Current concomitant medication Data on Infection

        -  Indication for diagnosis and treatment

        -  Upper Gastrointestinal tract symptoms

        -  Diagnostic Test for current treatment

        -  Number and type of previous eradication attempts Prescribed Treatment

        -  Drugs

        -  Dosage and intakes per day

        -  Length of treatment Compliance

        -  Adherence to treatment (yes/no &gt;90%) Adverse Events

        -  Type of event, intensity, duration and relation with treatment

        -  Treatment withdrawal due to adverse events. Efficacy

        -  Eradication (yes/no), test used, and date
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prescribed treatment for H. pylori</measure>
    <time_frame>1 year</time_frame>
    <description>Drugs
Dosage and intakes
Length of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>1 year</time_frame>
    <description>Type, intensity, duration and relation with treatment
Treatment withdrawal due to adverse event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>1 year</time_frame>
    <description>Eradication (yes/no), test used and date</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anonymised patient identifiers</measure>
    <time_frame>1 year</time_frame>
    <description>Country/Centre/Investigator
Autonumeric Patient identifier number
Gender
Date of Birth
Ethnic Background</description>
  </secondary_outcome>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>H. Pylori Infection</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Infected adult patients by Helicobacter pylori
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Infected adult patients by Helicobacter pylori

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Javier Pérez Gisbert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundación de Investigación Biomédica - Hospital Universitario de La Princesa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Javier Pérez Gisbert, MD</last_name>
    <phone>+34 913093911</phone>
    <email>javier.p.gisbert@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University Wien</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Athanasios AM Makristathis, L.C.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Charleroi, Charleroi</name>
      <address>
        <city>Charleroi</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vicent VL Vicent Lamy</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of Sofia</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>L. Boyanova</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Merkur</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miroslava Katicic</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charles University Faculty of Medicine</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Bures</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Køge University Hospital</name>
      <address>
        <city>Køge</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Bytzer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Tartu</name>
      <address>
        <city>Tartu</city>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heidi Maaroos</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herttoniemi Hospital, Helsinki</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lea Veijola</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>F. Megraud</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizin Uni Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Malfertheiner, L.C.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Clinic, Henry Dunant Hospital</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theodore Rokkas</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ferencváros Health Centre, Gaastroenterology</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>György M.Buzás</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Adelaide Meath Hospital, Dublin</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>C. O'Morain</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Studio Gasbarrini</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A. Gasbarrini</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Digestive Diseases Centre GASTRO</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcis Leja</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lithuanian university of Health Sciences Hospital</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Limas Kupcinskas</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ikazia Ziekenhuis/ Erasmus Medisch Centrum</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>L. Capelle</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central Hospital of Ostfold</name>
      <address>
        <city>Fredrikstad</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frode Lerang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Departament of Gastroenterology, Medical Centre for Postgraduate Education</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krzysztof Przytulski</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Porto</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Carlos Machado</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Timisoara</name>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrian Goldis</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central Scientific Research Institute of Gastroenterology</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dmitry Bordin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Center of Serbia</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomica Milosavljevic</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>DC Rogaska</name>
      <address>
        <city>Rogaska Slatina</city>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bojan Tepes</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de La Princesa, Madrid</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J P. Gisbert</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital.</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Per Hellström</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Beglinger</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dokuz Eylul University School of Medicine</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilkay Simsek</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Medical University</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oleg Shvets</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leeds General Infirmiry Hospital</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>T. Axon</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Croatia</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Slovenia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Arkkila PE, Seppälä K, Kosunen TU, Sipponen P, Mäkinen J, Rautelin H, Färkkilä M. Helicobacter pylori eradication as the sole treatment for gastric and duodenal ulcers. Eur J Gastroenterol Hepatol. 2005 Jan;17(1):93-101.</citation>
    <PMID>15647648</PMID>
  </reference>
  <reference>
    <citation>Azevedo NF, Huntington J, Goodman KJ. The epidemiology of Helicobacter pylori and public health implications. Helicobacter. 2009 Sep;14 Suppl 1:1-7. doi: 10.1111/j.1523-5378.2009.00703.x. Review. Erratum in: Helicobacter. 2010 Feb;15(1):78.</citation>
    <PMID>19712161</PMID>
  </reference>
  <reference>
    <citation>Broutet N, Tchamgoué S, Pereira E, Lamouliatte H, Salamon R, Mégraud F. Risk factors for failure of Helicobacter pylori therapy--results of an individual data analysis of 2751 patients. Aliment Pharmacol Ther. 2003 Jan;17(1):99-109.</citation>
    <PMID>12492738</PMID>
  </reference>
  <reference>
    <citation>de Vries AC, van Grieken NC, Looman CW, Casparie MK, de Vries E, Meijer GA, Kuipers EJ. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology. 2008 Apr;134(4):945-52. doi: 10.1053/j.gastro.2008.01.071. Epub 2008 Jan 30.</citation>
    <PMID>18395075</PMID>
  </reference>
  <reference>
    <citation>Ford A, Moayyedi P. How can the current strategies for Helicobacter pylori eradication therapy be improved? Can J Gastroenterol. 2003 Jun;17 Suppl B:36B-40B.</citation>
    <PMID>12845349</PMID>
  </reference>
  <reference>
    <citation>Ford AC, Axon AT. Epidemiology of Helicobacter pylori infection and public health implications. Helicobacter. 2010 Sep;15 Suppl 1:1-6. doi: 10.1111/j.1523-5378.2010.00779.x. Review.</citation>
    <PMID>21054646</PMID>
  </reference>
  <reference>
    <citation>Gisbert JP, Calvet X. Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. Aliment Pharmacol Ther. 2011 Dec;34(11-12):1255-68. doi: 10.1111/j.1365-2036.2011.04887.x. Epub 2011 Oct 21. Review.</citation>
    <PMID>22017749</PMID>
  </reference>
  <reference>
    <citation>Gisbert JP, Calvet X, O'Connor A, Mégraud F, O'Morain CA. Sequential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol. 2010 May-Jun;44(5):313-25. doi: 10.1097/MCG.0b013e3181c8a1a3. Review.</citation>
    <PMID>20054285</PMID>
  </reference>
  <reference>
    <citation>Gisbert JP, Calvet X. Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. Aliment Pharmacol Ther. 2011 Sep;34(6):604-17. doi: 10.1111/j.1365-2036.2011.04770.x. Epub 2011 Jul 11. Review.</citation>
    <PMID>21745241</PMID>
  </reference>
  <reference>
    <citation>Gisbert JP, Khorrami S, Carballo F, Calvet X, Gené E, Dominguez-Muñoz JE. H. pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. Cochrane Database Syst Rev. 2004;(2):CD004062. Review.</citation>
    <PMID>15106235</PMID>
  </reference>
  <reference>
    <citation>Graham DY, Rimbara E. Understanding and appreciating sequential therapy for Helicobacter pylori eradication. J Clin Gastroenterol. 2011 Apr;45(4):309-13. doi: 10.1097/MCG.0b013e31820ac05e.</citation>
    <PMID>21389810</PMID>
  </reference>
  <reference>
    <citation>Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010 Aug;59(8):1143-53. doi: 10.1136/gut.2009.192757. Epub 2010 Jun 4. Review.</citation>
    <PMID>20525969</PMID>
  </reference>
  <reference>
    <citation>Greenberg ER, Anderson GL, Morgan DR, Torres J, Chey WD, Bravo LE, Dominguez RL, Ferreccio C, Herrero R, Lazcano-Ponce EC, Meza-Montenegro MM, Peña R, Peña EM, Salazar-Martínez E, Correa P, Martínez ME, Valdivieso M, Goodman GE, Crowley JJ, Baker LH. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet. 2011 Aug 6;378(9790):507-14. doi: 10.1016/S0140-6736(11)60825-8. Epub 2011 Jul 21.</citation>
    <PMID>21777974</PMID>
  </reference>
  <reference>
    <citation>Hsu PI, Wu DC, Wu JY, Graham DY. Is there a benefit to extending the duration of Helicobacter pylori sequential therapy to 14 days? Helicobacter. 2011 Apr;16(2):146-52. doi: 10.1111/j.1523-5378.2011.00829.x.</citation>
    <PMID>21435093</PMID>
  </reference>
  <reference>
    <citation>Ikenberry SO, Harrison ME, Lichtenstein D, Dominitz JA, Anderson MA, Jagannath SB, Banerjee S, Cash BD, Fanelli RD, Gan SI, Shen B, Van Guilder T, Lee KK, Baron TH; ASGE STANDARDS OF PRACTICE COMMITTEE. The role of endoscopy in dyspepsia. Gastrointest Endosc. 2007 Dec;66(6):1071-5. Epub 2007 Oct 29.</citation>
    <PMID>18028927</PMID>
  </reference>
  <reference>
    <citation>Maconi G, Sainaghi M, Molteni M, Bosani M, Gallus S, Ricci G, Alvisi V, Porro GB. Predictors of long-term outcome of functional dyspepsia and duodenal ulcer after successful Helicobacter pylori eradication--a 7-year follow-up study. Eur J Gastroenterol Hepatol. 2009 Apr;21(4):387-93. doi: 10.1097/MEG.0b013e3283069db0.</citation>
    <PMID>19182682</PMID>
  </reference>
  <reference>
    <citation>Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ; European Helicobacter Study Group. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut. 2012 May;61(5):646-64. doi: 10.1136/gutjnl-2012-302084.</citation>
    <PMID>22491499</PMID>
  </reference>
  <reference>
    <citation>McColl KE. Clinical practice. Helicobacter pylori infection. N Engl J Med. 2010 Apr 29;362(17):1597-604. doi: 10.1056/NEJMcp1001110. Review.</citation>
    <PMID>20427808</PMID>
  </reference>
  <reference>
    <citation>McNicholl AG, Linares PM, Nyssen OP, Calvet X, Gisbert JP. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 2012 Sep;36(5):414-25. doi: 10.1111/j.1365-2036.2012.05211.x. Epub 2012 Jul 15.</citation>
    <PMID>22803691</PMID>
  </reference>
  <reference>
    <citation>Moayyedi P. The health economics of Helicobacter pylori infection. Best Pract Res Clin Gastroenterol. 2007;21(2):347-61. Review.</citation>
    <PMID>17382282</PMID>
  </reference>
  <reference>
    <citation>Moayyedi P, Deeks J, Talley NJ, Delaney B, Forman D. An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews. Am J Gastroenterol. 2003 Dec;98(12):2621-6. Review.</citation>
    <PMID>14687807</PMID>
  </reference>
  <reference>
    <citation>Niv Y, Hazazi R. Helicobacter pylori recurrence in developed and developing countries: meta-analysis of 13C-urea breath test follow-up after eradication. Helicobacter. 2008 Feb;13(1):56-61. doi: 10.1111/j.1523-5378.2008.00571.x.</citation>
    <PMID>18205667</PMID>
  </reference>
  <reference>
    <citation>Oderda G, Shcherbakov P, Bontems P, Urruzuno P, Romano C, Gottrand F, Gómez MJ, Ravelli A, Gandullia P, Roma E, Cadranel S, De Giacomo C, Canani RB, Rutigliano V, Pehlivanoglu E, Kalach N, Roggero P, Celinska-Cedro D, Drumm B, Casswall T, Ashorn M, Arvanitakis SN; European Pediatric Task Force on Helicobacter pylori. Results from the pediatric European register for treatment of Helicobacter pylori (PERTH). Helicobacter. 2007 Apr;12(2):150-6.</citation>
    <PMID>17309752</PMID>
  </reference>
  <reference>
    <citation>Rokkas T, Sechopoulos P, Robotis I, Margantinis G, Pistiolas D. Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen. Am J Gastroenterol. 2009 Jan;104(1):21-5. doi: 10.1038/ajg.2008.87.</citation>
    <PMID>19098844</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2014</study_first_submitted>
  <study_first_submitted_qc>December 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2014</study_first_posted>
  <last_update_submitted>February 10, 2016</last_update_submitted>
  <last_update_submitted_qc>February 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fundación de Investigación Biomédica - Hospital Universitario de La Princesa</investigator_affiliation>
    <investigator_full_name>Javier P. Gisbert</investigator_full_name>
    <investigator_title>Javier P. Gisbert MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

